To study the effect of Unani medicine in urticaria
Phase 3
- Conditions
- Health Condition 1: L509- Urticaria, unspecified
- Registration Number
- CTRI/2023/11/059929
- Lead Sponsor
- Dr. Juveria Parveen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1. Age between 18 - 55 years
2. Patients of either sex
3. Mild to severe pruiritis
4. Skin eruptions, itching and burning sensation
Exclusion Criteria
Patients with
1. Angioedema without wheals
2. Urticarial vasculitis
3. Severe acute/chronic urticaria
4. Pregnant and lactating women
5. Uncontrolled Hypertension and DM
6. SLE
7. Anaphylactic shock
8. Co morbid conditions like cardiac, respiratory, renal disorders and Carcinoma
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Outcome depends on Urticria Activity Score (UAS)Timepoint: Symptoms to be reviewed within 45 days
- Secondary Outcome Measures
Name Time Method Relief in symptoms such as itching, rednessTimepoint: Symptoms will be assessed within 45 days